| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | KU-60019 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.0008 |
| mRNA | AZD8055 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0009 |
| mRNA | AZD6482 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.001 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | -0.11 | 0.002 |
| mRNA | temsirolimus | CTRPv2 | pan-cancer | AAC | 0.15 | 0.002 |
| mRNA | Rapamycin | CTRPv2 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | -0.17 | 0.003 |
| mRNA | GDC-0941 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.003 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.097 | 0.003 |
| mRNA | MK-2206 | CTRPv2 | pan-cancer | AAC | 0.099 | 0.005 |